Non Alcoholic Fatty Liver Disease Pipeline Outlook, FDA Approvals, Clinical Trials And Companies 2024

(MENAFN- GetNews)

DelveInsight's,
“Non-Alcoholic Fatty Liver Disease Pipeline Insight 2024”
report provides comprehensive insights about
80+ companies and 100+ pipeline drugs
in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the Non Alcoholic Fatty Liver Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Alcoholic Fatty Liver Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Non Alcoholic Fatty Liver Disease Pipeline Report

• DelveInsight's Non Alcoholic Fatty Liver Disease pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Non Alcoholic Fatty Liver Disease treatment.
• The leading Non Alcoholic Fatty Liver Disease Companies working in the market include Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, and others.
• Promising Non Alcoholic Fatty Liver Disease Therapies in the various stages of development include Semaglutide, Ursodeoxycholic Acid, INI-822 (A), HEC96719, and others.
• May 2024:- Corcept Therapeutics- The primary objective of this study is to determine the effect of hepatic impairment on the pharmacokinetics (PK) of miricorilant following a single oral dose by comparing participants with normal hepatic function with participants with moderate hepatic impairment with or without nonalcoholic steatohepatitis (NASH).
• May 2024:- Novo Nordisk A/S- The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis. The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.

Request a sample and discover the recent advances in Non Alcoholic Fatty Liver Disease treatment drugs @ Non Alcoholic Fatty Liver Disease Pipeline Outlook Report

Non Alcoholic Fatty Liver Disease Overview

Non-alcoholic fatty liver disease (NAFLD) is a broad term used to cover a spectrum of conditions that are characterized by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis or hereditary disorders. The prevalence of NAFLD in western countries is around 20 to 30%.

Non Alcoholic Fatty Liver Disease Emerging Drugs Profile

• Lanifibranor: Inventiva Pharma
• ZED 1227: Dr. Falk Pharma GmbH
• TVB-2640: Sagimet Biosciences
• ALS-L1023: AngioLab

Find out more about Non Alcoholic Fatty Liver Disease treatment drugs @ Drugs for Non Alcoholic Fatty Liver Disease Treatment

Non Alcoholic Fatty Liver Disease Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Non-Alcoholic Fatty Liver Disease. The companies which have their Non-Alcoholic Fatty Liver Disease drug candidates in the most advanced stage, i.e. phase III include, Inventiva Pharma.

DelveInsight's Non Alcoholic Fatty Liver Disease pipeline report covers around
100+ products
under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Learn more about the emerging Non Alcoholic Fatty Liver Disease pipeline therapies @ Non Alcoholic Fatty Liver Disease Clinical Trials

Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Non Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Non Alcoholic Fatty Liver Disease Companies

Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, and others.

Dive deep into rich insights for new drugs for Non Alcoholic Fatty Liver Disease Treatment, visit @ Non Alcoholic Fatty Liver Disease Drugs

Scope of the Non Alcoholic Fatty Liver Disease Pipeline Report

• Coverage- Global
• Non Alcoholic Fatty Liver Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non Alcoholic Fatty Liver Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Non Alcoholic Fatty Liver Disease Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, and others.
• Non Alcoholic Fatty Liver Disease Therapies- Semaglutide, Ursodeoxycholic Acid, INI-822 (A), HEC96719, and others.

For further information on the Non Alcoholic Fatty Liver Disease Pipeline Therapeutics, reach out @ Non Alcoholic Fatty Liver Disease Treatment Drugs

Table of Content

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.